0001562180-23-008172.txt : 20231206 0001562180-23-008172.hdr.sgml : 20231206 20231206172023 ACCESSION NUMBER: 0001562180-23-008172 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231204 FILED AS OF DATE: 20231206 DATE AS OF CHANGE: 20231206 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pine Michael Craig CENTRAL INDEX KEY: 0001904458 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51122 FILM NUMBER: 231470526 MAIL ADDRESS: STREET 1: C/O EYEPOINT PHARMACEUTICALS, INC. STREET 2: 480 PLEASANT STREET, SUITE A-210 CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001314102 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 262774444 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-926-5000 MAIL ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: pSivida Corp. DATE OF NAME CHANGE: 20080619 FORMER COMPANY: FORMER CONFORMED NAME: pSivida LTD DATE OF NAME CHANGE: 20050111 4 1 primarydocument.xml PRIMARY DOCUMENT X0508 4 2023-12-04 false 0001314102 EyePoint Pharmaceuticals, Inc. EYPT 0001904458 Pine Michael Craig 480 PLEASANT ST, STE A210 WATERTOWN MA 02472 false true false false Chief Corp Dev.&Strat. Officer true Common Stock 2023-12-04 4 M false 45000.00 12.62 A 50343.00 D Common Stock 2023-12-04 4 S false 45000.00 22.00 D 5343.00 D Stock Option (Right to Buy) 12.62 2023-12-04 4 M false 45000.00 0.00 D 2032-01-10 Common Stock 45000.00 55000.00 D Includes 2,159 shares acquired on January 31, 2023 and 2,184 shares acquired on July 31,2023 pursuant to EyePoint's 2019 Employee Stock Purchase Plan. The option to purchase will vest and become exercisable as follows: 25% at January 10th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years. /s/ Ron Honig, Attorney-in-Fact 2023-12-06